For the past 20 of his more than 30 years in practice, Dan has specialized in supporting the business development teams of leading life sciences companies like Zimmer Biomet Holdings, Eli Lilly and Company, and Baxter Healthcare, and the senior management teams of successful biotechnology companies such as Endocyte, Inc., CoLucid Pharmaceuticals and Marcadia Biotech. He has been lead counsel in more than 100 strategic transactions, including domestic and international acquisitions and divestitures, in-licensing and out-licensing transactions, exclusive distribution arrangements, product development and collaboration agreements, multi-party joint ventures, strategic investments, and venture capital financings.
Outside General Counsel
Dan has served as outside general counsel to more than a dozen biotechnology and medical device companies developing life-saving medicines and technologies in fields such as oncology, neuroscience, cardiology and diabetes.
Dan completed the Biotechnology for Business program at Duke University in 2004.